

Steven Le Guill

Professor Steven Le Guill is the Director of the Institut Curie Hospital group (Paris, Saint-Cloud, Orsay; France), Since 2021.

He is a MD with specializing in Hematology, graduated from the Medical University of Nantes and a PhD with specialization in “blood cells biology”, graduated from Université Paris Cité (former Descartes Paris). Professor Le Guill has been a post-doc at Dana-Farber Cancer Institute (Harvard Medical School, Boston, USA). He has been appointed University Professor in 2010 at Nantes Medical University until 2022 and then at Versailles Saint-Quentin Medical University.

He served at Nantes Medical University (France) from 1996 to 2021, where he was Head of the Hematology Department (2018-2021), Head of the Oncology and Immunology PHU (2021) and Head of the Early Phase Clinical Investigation Unit (2013-2021). From 2016 to 2021, he has been a member of the management board of Nantes University Hospital and Medical Director of the Clinical Research Department and investigation (DRCI) from 2013 to 2017.

Professor Le Guill is an international expert in lymphoma with high focus on Mantle cell lymphoma, a rare lymphoma entity. He published as first author in major international peer review journals, including in the New England Journal of Medecine, Journal of Clinical Oncology, British Journal of Medecine, Blood. He is a member of the management board of the LYSA (Lymphoma Study Association) for which he is a member of the executive Board. He is a member of numerous academic societies, including The French society of Hematology (SFH), American Society of Hematology (ASH) and European Society of Medical Oncology (ESMO). Professor Le Guill has also been the National Coordinator of the French National CAR-T Registry (DESCAR-T).

Professor Le Guill was awarded numerous prizes in his field of expertise, including the Prize of the French Society of Hematology in 2017.